H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (NASDAQ:LGND) on Wednesday, setting a price target of $310, which is approximately 168.21% above the present share price of $115.58.
Pantginis expects Ligand Pharma to post earnings per share (EPS) of $1.84 for the third quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Strong Buy rating of shares in Ligand Pharma, with an average price target of $224.67.
The analysts price targets range from a high of $310 to a low of $174.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $84.68 million and a net profit of $45.74 million. The company's market cap is $1.93 billion.
According to TipRanks.com, H.C. Wainwright analyst Joseph Pantginis is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 14.7% and a 38.27% success rate.
Ligand Pharmaceuticals , Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.